JP2024517829A - メタドンを含む胃内滞留システム - Google Patents

メタドンを含む胃内滞留システム Download PDF

Info

Publication number
JP2024517829A
JP2024517829A JP2023568006A JP2023568006A JP2024517829A JP 2024517829 A JP2024517829 A JP 2024517829A JP 2023568006 A JP2023568006 A JP 2023568006A JP 2023568006 A JP2023568006 A JP 2023568006A JP 2024517829 A JP2024517829 A JP 2024517829A
Authority
JP
Japan
Prior art keywords
segment
weight
arms
methadone
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568006A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517829A5 (enExample
Inventor
ビギン エステレ
カールトン パトリシア
カトストラ ジェフリー
アルトルーター デイビッド
ジャラミロ モンテスコ ジュアン
ピムパレード マンジート
Original Assignee
リンドラ セラピューティクス， インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リンドラ セラピューティクス， インコーポレイティド filed Critical リンドラ セラピューティクス， インコーポレイティド
Publication of JP2024517829A publication Critical patent/JP2024517829A/ja
Publication of JP2024517829A5 publication Critical patent/JP2024517829A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2023568006A 2021-05-05 2022-05-04 メタドンを含む胃内滞留システム Pending JP2024517829A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163184760P 2021-05-05 2021-05-05
US63/184,760 2021-05-05
PCT/US2022/072115 WO2022236289A1 (en) 2021-05-05 2022-05-04 Gastric residence systems comprising methadone

Publications (2)

Publication Number Publication Date
JP2024517829A true JP2024517829A (ja) 2024-04-23
JP2024517829A5 JP2024517829A5 (enExample) 2025-05-09

Family

ID=83932453

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568006A Pending JP2024517829A (ja) 2021-05-05 2022-05-04 メタドンを含む胃内滞留システム

Country Status (8)

Country Link
US (1) US20240335400A1 (enExample)
EP (1) EP4333824A4 (enExample)
JP (1) JP2024517829A (enExample)
CN (1) CN117615755A (enExample)
AU (1) AU2022270208A1 (enExample)
CA (1) CA3216743A1 (enExample)
IL (1) IL308211A (enExample)
WO (1) WO2022236289A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020117855A1 (en) 2018-12-03 2020-06-11 Lyndra, Inc. Stomach simulating device
BR112021018496A2 (pt) 2019-03-20 2021-11-30 Lyndra Therapeutics Inc Cápsulas e revestimento de cápsula para formas de dosagem de residência gástrica
AU2020242062B2 (en) 2019-03-20 2025-12-11 Nortiva Bio, Inc. Coatings for gastric residence dosage forms

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013530193A (ja) * 2010-07-06 2013-07-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｇａｂａ類似体及びオピオイドを含む新規胃内滞留型剤形
JP2019501110A (ja) * 2015-10-23 2019-01-17 リンドラ，インコーポレイティド 治療薬の持続放出用の胃内滞留システム及びその使用方法
JP2019529543A (ja) * 2016-09-13 2019-10-17 ▲ユ▼展新藥生技股分有限公司Ａｌａｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ブプレノルフィン徐放性製剤
JP2019532947A (ja) * 2016-09-30 2019-11-14 リンドラ，インコーポレイティド アダマンタン系薬物の持続的送達のための胃内滞留システム
JP2020523306A (ja) * 2017-06-09 2020-08-06 リンドラ，インコーポレイティド 放出速度調節フィルムを有する胃内滞留システム

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013369379B2 (en) * 2012-12-27 2018-03-15 Hennig Arzneimittel Gmbh & Co. Kg Monolithic dosage form for the modified release of an active ingredient combination
WO2017100367A1 (en) * 2015-12-08 2017-06-15 Lyndra, Inc. Geometric configurations for gastric residence systems

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013530193A (ja) * 2010-07-06 2013-07-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｇａｂａ類似体及びオピオイドを含む新規胃内滞留型剤形
JP2019501110A (ja) * 2015-10-23 2019-01-17 リンドラ，インコーポレイティド 治療薬の持続放出用の胃内滞留システム及びその使用方法
JP2019529543A (ja) * 2016-09-13 2019-10-17 ▲ユ▼展新藥生技股分有限公司Ａｌａｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ブプレノルフィン徐放性製剤
JP2019532947A (ja) * 2016-09-30 2019-11-14 リンドラ，インコーポレイティド アダマンタン系薬物の持続的送達のための胃内滞留システム
JP2020523306A (ja) * 2017-06-09 2020-08-06 リンドラ，インコーポレイティド 放出速度調節フィルムを有する胃内滞留システム

Also Published As

Publication number Publication date
AU2022270208A1 (en) 2023-12-07
EP4333824A1 (en) 2024-03-13
IL308211A (en) 2024-01-01
CA3216743A1 (en) 2022-11-10
EP4333824A4 (en) 2025-04-09
WO2022236289A1 (en) 2022-11-10
CN117615755A (zh) 2024-02-27
US20240335400A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
US20240423909A1 (en) Materials architecture for gastric residence systems
CN114945355B (zh) 具有用于改进胃驻留的长丝的胃驻留系统
JP2024517829A (ja) メタドンを含む胃内滞留システム
US20240390270A1 (en) Gastric residence systems for administration of risperidone
US20250339368A1 (en) Dosage forms for gastric retention
JP2024518156A (ja) ブプレノルフィンとナロキソンを含む胃内滞留システム
JP2025531626A (ja) 胃内滞留システムを用いたリスペリドンの投与レジメン
IL292848A (en) Polymeric linkers for a gastric residence system
US20240398701A1 (en) Manufacturing methods for gastric residence systems
CN117083059A (zh) 用于利培酮施用的胃滞留系统
TWI837082B (zh) 用於胃滯留系統之材料架構
WO2025199123A1 (en) Flexible line configurations for gastric residence systems
TW202500122A (zh) 用於胃滯留系統之材料架構
CN118871091A (zh) 用于胃滞留的剂型

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250428

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260210